Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.

Ahmed AtiaHeba AboeldahabAhmed WageehMohamed ElnenyMohamed ElmallahyBashaer ElawfiMenna M AboelkhierAmr ElrosasyMaya Magdy AbdelwahabSomaya SayedAhmed Abdelaziz

Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2024)

PCSK9i was associated with better lipid profile and quality of life of patients and can be recommended as an optimal treatment strategy. Further trials should study combinations of PCSK9i with other lipid-lowering drugs.

Keyphrases

acute coronary syndrome
end stage renal disease
low density lipoprotein
ejection fraction
chronic kidney disease
newly diagnosed
systematic review
prognostic factors
percutaneous coronary intervention
antiplatelet therapy
fatty acid
atrial fibrillation
drug induced